Evolution of procurement of medical devices in Italy

12

Dec 2018

In late October 2018, Assobiomedica, the body that represents the companies that operate in the medical device sector, published the fourth edition of the document “Public policies for the purchase of medical devices.”

Italian healthcare system is highly regionalized. Even within the regions, there has not been quite a lot of cooperation traditionally. Thus, the medical device companies may have more leverage when negotiating with one entity, rather than with a group of entities. Many incentives have existed (or still exist) whose aim was to organize a well-functioning body, which would take care of procurement on the regional level. However, the success of these incentives varied among the Italian regions.

This document (“Public policies for the purchase of medical devices”) has been developed by the Tender Observatory, which is composed of Assobiomedica Study Center (CSA) and European Research Center (CER). They have stratified four (4) types of acquisitions:

  • Single acquisitions, made by separate healthcare facilities
  • Group acquisitions, made by groups of healthcare facilities, with specific characteristics for every group
  • Centralized regional acquisitions, made by the regional centers for procurement
  • Purchases made through Consip, a public company in charge of public procurement

Below are some of the interesting conclusions from the publication:

  • In 2007, 95% of the total amount awarded in the public tenders consisted of the single or group acquisitions, while the remainder consisted of centralized regional acquisitions. In 2017, this ratio was 35% and 65%, respectively. The percentage of purchases made through Consip are neglectable
  • There is a negative trend of the number of healthcare facilities participating in one tender; for example, in 2009, on average eight (8) entities engaged in the centralized regional acquisitions, while the average for 2017 is only three (3)
  • In 2007, 30% of the tenders were accomplished within one year, 40% within 18 months and for the last 30%, the process lasted more than 18 months. In 2017, 55% of the tenders were accomplished within less than 6 months
  • There is no rule which could explain the difference among the regions in the period 2007-2017. Campania region in the south of Italy leads, with more than 70% of the acquisitions being centralized regional acquisitions. On the other hand, less than 5% of the purchases in Sicily and Sardinia were centralized regional acquisitions. In Lombardy, the percentage of the centralized regional procurement is 35%, in Emilia Romagna 30% and in Veneto 40%, with the remaining percentage being the mix of single and group acquisitions.

See the full report in Italian here, which also contains the list of the regional procurement bodies.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more

04

Mar 2022

On February 14, 2022, the Danish Treatment Council (Behandlingsråd), a new body for assessing treatments and health technologies that became fully operational in late May 2021, has announced its symposium, which will take place in Aalborg on May 11, 2022.

Read more

14

Feb 2022

On January 28, 2022, the Institute for the Hospital Remuneration System (InEK) has published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2021. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.

Read more

07

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Read more